Antengene Inks Clinical Collaboration With Msd To Evaluate Atg 037 In Combo With Keytruda In Patients With Locally Advanced Or Metastatic Solid Tumours
Antengene inks clinical collaboration with MSD to evaluate ATG 037 in combo with Keytruda in patients with locally advanced or metastatic solid tumours
Antengene Corporation Limited, a leading commercial-stage innovative, global biopharmaceutical company, announced it has entered into a global clinical collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) on a multicenter, open-label, phase I dose-finding study of ATG-037 as a monotherapy and in combination with MSD
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!